Are you Dr. Bright?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 26 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
13821 Village Mill Dr
Ste B
Midlothian, VA 23114Phone+1 804-794-8900Fax+1 804-378-2012
Summary
- Dr. George Bright, MD is a board certified pediatrician in Midlothian, Virginia. He is currently licensed to practice medicine in Virginia and Texas. He is affiliated with Bon Secours St. Mary's Hospital.
Education & Training
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1967 - 1968
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Pediatrics, 1963 - 1964
University of Texas Southwestern Medical CenterResidency, Pediatrics, 1962 - 1963- University of Arkansas for Medical Sciences (UAMS) College of MedicineInternship, Transitional Year, 1961 - 1962
University of Texas Southwestern Medical SchoolClass of 1961
Certifications & Licensure
VA State Medical License 1968 - 2026
TX State Medical License 1961 - 1988- American Board of Pediatrics Pediatrics
Clinical Trials
- ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry Start of enrollment: 2011 Aug 01
Publications & Presentations
PubMed
- 9 citationsWhen is a positive test for pediatric growth hormone deficiency a true positive testGeorge M. Bright, Peter A Morris, Ron G. Rosenfeld
Hormone Research in Paediatrics. 2021-12-02 - 4 citationsA rationale for the treatment of short stature in children with the combination of recombinant human growth hormone (rhGH) and recombinant human insulin-like growth fa...George M. Bright, Juan Francisco Fierro-Renoy
Growth Hormone & IGF Research. 2020-06-01 - 11 citationsRecombinant IGF-I: Past, present and future.George M. Bright
Growth Hormone & IGF Research. 2016-06-01
Press Mentions
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
Richmond Drugmaker Draws National Backlash for Anti-Overdose Price HikeFebruary 14th, 2017
